Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology ...

This report is tailored for C-level executives, business development professionals, licensing managers, legal advisors, and anyone involved in pharmaceutical and biotechnology deal-making. It provides ...
Business Wire

Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 ...

DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology ...
Business Wire

Global Royalty Rate Trends in Pharma and Biotech Dealmaking Analysis Report 2023: Technology Licensed, Royalty Rates, License Fees, Upfront and Milestone Payments ...

DUBLIN--(BUSINESS WIRE)--The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023" report has been added to ResearchAndMarkets.com's offering. The Global Royalty Rate Trends in ...
Hosted on MSN

Microsoft secures decade of royalty-free OpenAI access in new deal

Microsoft has restructured its partnership with OpenAI, ending exclusive rights but securing royalty-free access to its AI models through 2032. The new arrangement allows OpenAI to work with other ...